Skip to main content

Table 1 Baseline patient characteristics at TAVR*

From: The role of cardiovascular magnetic resonance in stratifying paravalvular leak severity after transcatheter aortic valve replacement: an observational outcome study

 

All (n = 23)

RF < 20% (n = 11)

RF > 20% (n = 12)

P value

Male

16 (70)

6 (55)

10 (83)

0.19

Age (mean ± SD)

83 ± 6

83 ± 7

82 ± 5

0.86

NYHA class (mean ± SD)

3.2 ± 0.7

3.1 ± 0.7

3.3 ± 0.8

0.61

STS-PROM (%; mean ± SD)

6.9 ± 2.4

6.4 ± 2.0

7.4 ± 2.7

0.33

Body mass index (kg/m2)

25 ± 4

25 ± 4

24 ± 4

0.64

Comorbidities

    

Coronary artery disease

13 (57)

7 (64)

6 (50)

0.68

CABG

7 (30)

2 (18)

5 (42)

 

PCI

8 (35)

4 (36)

4 (33)

 

Myocardial infarction

7 (30)

3 (27)

4 (33)

 

Atrial fibrillation

10 (44)

2 (18)

8 (67)

0.04

Diabetes mellitus

10 (44)

5 (46)

5 (42)

1.00

Hypertension

21 (91)

10 (91)

11 (92)

1.00

Serum creatinine

>1.5 mg/dl

8 (35)

2 (18)

6 (50)

0.19

COPD

8 (35)

3 (27)

5 (42)

0.67

Laboratory

    

Creatinine (mg/dl; median [IQR])

1.11 (0.90, 1.61)

1.07 (1.00, 1.30)

1.45 (0.86, 1.89)

0.18

BNP (pg/ml; median [IQR])

545 (226, 1612)

297 (197, 843)

1385 (360, 1806)

0.17

Echocardiography

    

Ejection fraction (%; mean ± SD)

47 ± 14

45 ± 13

49 ± 15

0.46

Aortic insufficiency* (mean ± SD)

1.1 ± 0.7

1.0 ± 0.7

1.1 ± 0.7

0.90

RVSP (mmHg; mean ± SD)

48 ± 17

43 ± 12

53 ± 19

0.17

RVSP >55 mmHg

7 (30)

2 (18)

5 (42)

0.37

Transfemoral approach

17 (74)

6 (55)

11 (92)

0.07

  1. *All results are presented as n (%) unless otherwise noted.
  2. BNP = brain natriuretic peptide, CABG = coronary artery bypass grafting, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, NYHA = New York Heart Association, PCI = percutaneous coronary intervention, RVSP = right ventricular systolic pressure, STS-PROM = Society of Thoracic Surgeons predicted risk of mortality, TAVR = transcatheter aortic valve replacement.